Back

Real world data on Solitary Plasmacytoma from eastern India- highlighting favorable trends in outcome

Podder, D.; Sonowal, H.; Saha, S.; Shah, B.; Ghosh, S.; Kumar, J.; Nag, A.; Chattyopadhyay, D.; Javed, R.; Rath, A.; Chakraborty, S.; Parihar, M.; Zameer, L.; Achari, R. B.; Nair, R.

2026-04-17 hematology
10.64898/2026.04.15.26350956 medRxiv
Show abstract

Introduction: Solitary plasmacytomas (SP) are rare neoplasm of localised proliferation of clonal plasma cells. It can be classified based on site of involvement and bone marrow involvement. It is an indolent disease in the majority of patients. Primary modality of treatment is radiotherapy and surgical excision. Materials and methods: This was a retrospective audit of SP who were treated and followed up at a tertiary care center in eastern India from January 2012 to December 2025. Patients who has solitary plasma cytoma with more than 10% plasma cells, POEMS syndrome, have been excluded from analysis. Results: We identified 46 patients of SP. The median age of the studied population was 53 years (23-75 years). Males were more commonly affected than females (M:F=2.2:1). Most common chief complaints were bony pain (67.4%). SBP was seen in 39 (84.8%) cases whereas SEP was seen in 7 (15.2%) cases. Vertebra was the most common site of involvement (61.4%). Median M band concentration 0.24 g/dL (0.1 to 1.95 gm/dL). IgG was the most common isotype accounting for 60.6% cases. Six cases (13%) had minimal bone marrow involvement. The majority of the patients received local radiotherapy (89.1%). With a median follow up of 5.4 years (95% CI: 1.8 - 9.0), median OS was not reached, median PFS was 9.22 years (95% CI: 5.8-12.6), median time to next treatment (TTNT) was 9.86 years (95% CI: 6.8 - 12.9). Conclusion: Solitary plasmacytoma commonly affects young males. Bones are more commonly affected than extramedullary sites. SP has a lower rate of progression and excellent prognosis when treated with local radiotherapy.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 14%
12.9%
2
Transactions of The Royal Society of Tropical Medicine and Hygiene
16 papers in training set
Top 0.1%
7.1%
3
British Journal of Haematology
15 papers in training set
Top 0.1%
7.1%
4
Heliyon
146 papers in training set
Top 0.1%
5.1%
5
Cureus
67 papers in training set
Top 0.8%
4.5%
6
Frontiers in Medicine
113 papers in training set
Top 1%
4.2%
7
BMC Public Health
147 papers in training set
Top 1%
3.8%
8
Medicine
30 papers in training set
Top 0.6%
3.2%
9
Public Health in Practice
11 papers in training set
Top 0.1%
3.0%
50% of probability mass above
10
Scientific Reports
3102 papers in training set
Top 43%
2.9%
11
International Journal of Infectious Diseases
126 papers in training set
Top 1.0%
2.2%
12
PeerJ
261 papers in training set
Top 4%
2.2%
13
European Journal of Neurology
20 papers in training set
Top 0.1%
2.2%
14
Diagnostics
48 papers in training set
Top 0.8%
2.0%
15
Tropical Medicine & International Health
15 papers in training set
Top 0.2%
2.0%
16
Vaccines
196 papers in training set
Top 1%
1.9%
17
Frontiers in Immunology
586 papers in training set
Top 4%
1.8%
18
PLOS Neglected Tropical Diseases
378 papers in training set
Top 3%
1.8%
19
Archives of Clinical and Biomedical Research
28 papers in training set
Top 0.6%
1.8%
20
Molecular Oncology
50 papers in training set
Top 0.3%
1.7%
21
Blood Advances
54 papers in training set
Top 0.8%
1.6%
22
Biomedicines
66 papers in training set
Top 2%
1.0%
23
Cancers
200 papers in training set
Top 4%
1.0%
24
Journal of Family Medicine and Primary Care
10 papers in training set
Top 0.5%
0.8%
25
Transplantation
13 papers in training set
Top 0.4%
0.8%
26
Clinical Chemistry and Laboratory Medicine (CCLM)
12 papers in training set
Top 0.2%
0.8%
27
Blood Cancer Journal
11 papers in training set
Top 0.2%
0.8%
28
Journal of Medical Virology
137 papers in training set
Top 4%
0.8%
29
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
30
BMC Cancer
52 papers in training set
Top 2%
0.8%